|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant
Lung Cancer Trial Collaborative Group, : Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al LACE Collaborative Group, : Lung adjuvant
cisplatin evaluation: A pooled analysis by the LACE Collaborative
Group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
International Trialist Association [ANITA]): A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zatloukal P, Petruzelka L, Zemanova M,
Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P and Pecen L:
Concurrent versus sequential chemoradiotherapy with cisplatin and
vinorelbine in locally advanced non-small cell lung cancer: A
randomized study. Lung Cancer. 46:87–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scheper RJ, Broxterman HJ, Scheffer GL,
Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML,
de Vries EG, van der Valk P, et al: Overexpression of a M(r)
110,000 vesicular protein in non-P-glycoprotein-mediated multidrug
resistance. Cancer Res. 53:1475–1479. 1993.PubMed/NCBI
|
|
7
|
Marchetti S, de Vries NA, Buckle T, Bolijn
MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O and
Schellens JH: Effect of the ATP-binding cassette drug transporters
ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva)
disposition in in vitro and in vivo pharmacokinetic studies
employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type
mice. Mol Cancer Ther. 7:2280–2287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ozvegy-Laczka C, Cserepes J, Elkind NB and
Sarkadi B: Tyrosine kinase inhibitor resistance in cancer: Role of
ABC multidrug transporters. Drug Resist Updat. 8:15–26. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger W, Setinek U, Hollaus P, Zidek T,
Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M:
Multidrug resistance markers P-glycoprotein, multidrug resistance
protein 1, and lung resistance protein in non-small cell lung
cancer: Prognostic implications. J Cancer Res Clin Oncol.
131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikuta K, Takemura K, Sasaki K, Kihara M,
Nishimura M, Ueda N, Naito S, Lee E, Shimizu E and Yamauchi A:
Expression of multidrug resistance proteins and accumulation of
cisplatin in human non-small cell lung cancer cells. Biol Pharm
Bull. 28:707–712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berger W, Elbling L, Hauptmann E and
Micksche M: Expression of the multidrug resistance-associated
protein (MRP) and chemoresistance of human non-small-cell lung
cancer cells. Int J Cancer. 73:84–93. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yano K: Lipid metabolic pathways as lung
cancer therapeutic targets: A computational study. Int J Mol Med.
29:519–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Futerman AH and Hannun YA: The complex
life of simple sphingolipids. EMBO Rep. 5:777–782. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cuvillier O and Levade T: Enzymes of
sphingosine metabolism as potential pharmacological targets for
therapeutic intervention in cancer. Pharmacol Res. 47:439–445.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morad SA and Cabot MC:
Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer.
13:51–65. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cuvillier O: Sphingosine in apoptosis
signaling. Biochim Biophys Acta. 1585:153–162. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pitson SM: Regulation of sphingosine
kinase and sphingolipid signaling. Trends Biochem Sci. 36:97–107.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maceyka M, Harikumar KB, Milstien S and
Spiegel S: Sphingosine-1-phosphate signaling and its role in
disease. Trends Cell Biol. 22:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cuvillier O, Ader I, Bouquerel P, Brizuela
L, Gstalder C and Malavaud B: Hypoxia, therapeutic resistance, and
sphingosine 1-phosphate. Adv Cancer Res. 117:117–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mendelson K, Evans T and Hla T:
Sphingosine 1-phosphate signalling. Development. 141:5–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cuvillier O: Downregulating sphingosine
kinase-1 for cancer therapy. Expert Opin Ther Targets.
12:1009–1020. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cuvillier O, Pirianov G, Kleuser B, Vanek
PG, Coso OA, Gutkind S and Spiegel S: Suppression of
ceramide-mediated programmed cell death by sphingosine-1-phosphate.
Nature. 381:800–803. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonhoure E, Pchejetski D, Aouali N,
Morjani H, Levade T, Kohama T and Cuvillier O: Overcoming
MDR-associated chemoresistance in HL-60 acute myeloid leukemia
cells by targeting sphingosine kinase-1. Leukemia. 20:95–102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pchejetski D, Golzio M, Bonhoure E, Calvet
C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J,
Malavaud B, et al: Sphingosine kinase-1 as a chemotherapy sensor in
prostate adenocarcinoma cell and mouse models. Cancer Res.
65:11667–11675. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guillermet-Guibert J, Davenne L,
Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C,
Delisle MB, Cuvillier O, Susini C and Bousquet C: Targeting the
sphingolipid metabolism to defeat pancreatic cancer cell resistance
to the chemotherapeutic gemcitabine drug. Mol Cancer Ther.
8:809–820. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pchejetski D, Bohler T, Brizuela L, Sauer
L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman
J, et al: FTY720 (fingolimod) sensitizes prostate cancer cells to
radiotherapy by inhibition of sphingosine kinase-1. Cancer Res.
70:8651–8661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brizuela L, Ader I, Mazerolles C, Bocquet
M, Malavaud B and Cuvillier O: First evidence of sphingosine
1-phosphate lyase protein expression and activity downregulation in
human neoplasm: Implication for resistance to therapeutics in
prostate cancer. Mol Cancer Ther. 11:1841–1851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gstalder C, Ader I and Cuvillier O: FTY720
(Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular
Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal
Model. Mol Cancer Ther. 15:2465–2474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ito H, Yoshida K, Murakami M, Hagiwara K,
Sasaki N, Kobayashi M, Takagi A, Kojima T, Sobue S and Suzuki M:
Heterogeneous sphingosine-1-phosphate lyase gene expression and its
regulatory mechanism in human lung cancer cell lines. Biochim
Biophys Acta. 1811:119–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Guan HY, Gong LY, Song LB, Zhang N,
Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of
sphingosine kinase-1 expression in human astrocytomas progression
and overall patient survival. Clin Cancer Res. 14:6996–7003. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Wang Y, Wan Z, Liu S, Cao Y and
Zeng Z: Sphingosine kinase 1 and cancer: A systematic review and
meta-analysis. PLoS One. 9:e903622014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruckhäberle E, Karn T, Denkert C, Loibl S,
Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani
S, et al: Predictive value of sphingosine kinase 1 expression in
neoadjuvant treatment of breast cancer. J Cancer Res Clin Oncol.
139:1681–1689. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sutphen R, Xu Y, Wilbanks GD, Fiorica J,
Grendys EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley
K, et al: Lysophospholipids are potential biomarkers of ovarian
cancer. Cancer Epidemiol Biomarkers Prev. 13:1185–1191.
2004.PubMed/NCBI
|
|
35
|
Malavaud B, Pchejetski D, Mazerolles C, de
Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier
O: Sphingosine kinase-1 activity and expression in human prostate
cancer resection specimens. Eur J Cancer. 46:3417–3424. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Serra M and Saba JD: Sphingosine
1-phosphate lyase, a key regulator of sphingosine 1-phosphate
signaling and function. Adv Enzyme Regul. 50:349–362. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oskouian B, Sooriyakumaran P, Borowsky AD,
Crans A, Dillard-Telm L, Tam YY, Bandhuvula P and Saba JD:
Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and
p38-dependent pathways and is down-regulated in colon cancer. Proc
Natl Acad Sci USA. 103:17384–17389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Min J, Van Veldhoven PP, Zhang L, Hanigan
MH, Alexander H and Alexander S: Sphingosine-1-phosphate lyase
regulates sensitivity of human cells to select chemotherapy drugs
in a p38-dependent manner. Mol Cancer Res. 3:287–296. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnson KR, Johnson KY, Crellin HG,
Ogretmen B, Boylan AM, Harley RA and Obeid LM: Immunohistochemical
distribution of sphingosine kinase 1 in normal and tumor lung
tissue. J Histochem Cytochem. 53:1159–1166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qin L, Liu S, Qin M, Wu W, Qin N, Fu Z, Xu
C, Huang J and Lai M: Down-regulation of sphingosine kinase 1
(SphK1) enhances the chemosensitivity to cisplatin in human colon
cancer RKO cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 33:623–629.
2017.(In Chinese). PubMed/NCBI
|
|
41
|
Matula K, Collie-Duguid E, Murray G,
Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, et
al: Regulation of cellular sphingosine-1-phosphate by sphingosine
kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy
resistance in gastroesophageal cancer. BMC Cancer. 15:7622015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao J, Tian ML and Song LP: The role of
SPHK-1 in non-small cell lung cancer drug-resistant cell line H460.
J Xi'an Jiaotong Univ. 38:172–175. 2017.(In Chinese).
|
